Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant

Transpl Infect Dis. 2014 Dec;16(6):1003-6. doi: 10.1111/tid.12306. Epub 2014 Nov 4.

Abstract

Transmission of hepatitis C virus (HCV) to recipients of hematopoietic stem cell transplant (HSCT) occurs frequently from HCV viremic donors and causes complications. Here, we report the outcomes of 3 cases from our 265 allogeneic HSCTs, whose donors had HCV infections. Successful prevention of HCV transmission was noted in 1 recipient by pretreatment of the donor with peginterferon/ribavirin to undetectable levels of HCV viremia before stem cell harvest. This case stressed the important role of effective antiviral therapy and HCV RNA seronegativity before cell harvest for prevention of HCV transmission in HSCT.

Keywords: HCV; HSCT; hematopoietic stem cell transplantation; hepatitis C virus; transmission prevention.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hepacivirus / isolation & purification
  • Hepatitis C / drug therapy
  • Hepatitis C / transmission*
  • Hepatitis C / virology
  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use
  • Male
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use
  • RNA, Viral / blood
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use
  • Tissue Donors
  • Viral Load
  • Viremia*

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a